444

TAIGEN BIOPHARMACEUTICALS HLDGS LTD

No trades
See on Supercharts
Market capitalization
‪11.81 B‬TWD
‪136.73 M‬TWD
‪123.13 M‬TWD
‪424.56 M‬
Beta (1Y)
−0.42

About TAIGEN BIOPHARMACEUTICALS HLDGS LTD

CEO
Kuo Long Huang
Headquarters
Taipei
Founded
2001
ISIN
KYG866171005
FIGI
BBG0055NWZ45
TaiGen Biopharmaceuticals Holdings Ltd. engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes-related complications. Its products include treatment fordrug-resistant bacterial infections Nemonoxacin, stem cell mobilizer Burixafor, anti-influenza drug TG-1000 and anti-hapatitis C virus drug Furaprevir. The company was founded on September 15, 2005 and is headquartered in Taipei, Taiwan.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 4157 is 15.60 TWD — it has decreased by 5.17% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange TAIGEN BIOPHARMACEUTICALS HLDGS LTD stocks are traded under the ticker 4157.
TAIGEN BIOPHARMACEUTICALS HLDGS LTD is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
4157 stock is 9.32% volatile and has beta coefficient of −0.42. Check out the list of the most volatile stocks — is TAIGEN BIOPHARMACEUTICALS HLDGS LTD there?
Yes, you can track TAIGEN BIOPHARMACEUTICALS HLDGS LTD financials in yearly and quarterly reports right on TradingView.
4157 stock has risen by 4.35% compared to the previous week, the month change is a 5.05% rise, over the last year TAIGEN BIOPHARMACEUTICALS HLDGS LTD has showed a 1.63% increase.
4157 net income for the last quarter is ‪185.67 M‬ TWD, while the quarter before that showed ‪−8.55 M‬ TWD of net income which accounts for ‪2.27 K‬% change. Track more TAIGEN BIOPHARMACEUTICALS HLDGS LTD financial stats to get the full picture.
Today TAIGEN BIOPHARMACEUTICALS HLDGS LTD has the market capitalization of ‪11.81 B‬, it has decreased by 2.24% over the last week.
No, 4157 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 4157 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TAIGEN BIOPHARMACEUTICALS HLDGS LTD stock right from TradingView charts — choose your broker and connect to your account.
4157 reached its all-time high on Aug 30, 2013 with the price of 139.60 TWD, and its all-time low was 8.20 TWD and was reached on Mar 26, 2020.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TAIGEN BIOPHARMACEUTICALS HLDGS LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TAIGEN BIOPHARMACEUTICALS HLDGS LTD stock shows the sell signal. See more of TAIGEN BIOPHARMACEUTICALS HLDGS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TAIGEN BIOPHARMACEUTICALS HLDGS LTD EBITDA is ‪−147.09 M‬ TWD, and current EBITDA margin is −119.46%. See more stats in TAIGEN BIOPHARMACEUTICALS HLDGS LTD financial statements.